Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661336 | 1.00 | HSD11B1 (0.51) | HSD11B1CHRM2CHRM1CHRM3CYP2D6 | |
| SCHEMBL30398589 | 0.87 | CYP2D6 (0.46) | HSD11B1CHRM2CHRM1CHRM3CYP2D6 | |
| SCHEMBL31662244 | 0.85 | HSD11B1 (0.47) | HSD11B1CHRM2CHRM1CHRM3CYP2D6 | |
| SCHEMBL30020135 | 0.85 | CYP2D6 (0.50) | CHRM1CYP2D6GPR119STSCYP1A2 | |
| SCHEMBL3973620 | 0.84 | HSD11B1 (0.49) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL12794680 | 0.84 | HSD11B1 (0.49) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL16499643 | 0.82 | HSD11B1 (0.47) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL30301990 | 0.81 | NR1H2 (0.47) | HSD11B1CYP2D6GPR119MMP13STS | |
| SCHEMBL184777 | 0.81 | CYP2D6 (0.60) | CYP2D6GPR119MMP13STS | |
| SCHEMBL2298971 | 0.80 | CYP2D6 (0.49) | HSD11B1CYP2D6GPR119MMP13STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4501925-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-118715216-A | Nitrogen-containing heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024114680-A9 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 海南先声再明医药股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
| WO-2024114680-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 海南先声再明医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| WO-2023185793-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-11053218-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-07-06 | — | — | US | disclosed |
| US-20200339704-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2020-10-29 | — | — | US | disclosed |
| EP-3697436-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3672949-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-12 | — | — | US | disclosed |
| US-10640489-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2019-09-17 | — | — | US | disclosed |
| WO-2019079569-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019038717-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339704-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | CRBN, RPS27A, COPB1 | HSD11B1 3432/4885CHRM2 4820/4885CHRM1 4864/4885 |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | HSD11B1 940/4885CHRM2 47/4885CHRM1 7/4885 |
| US-20240384007-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | CRBN, RPS27A, COPB1 | HSD11B1 3432/4885CHRM2 4820/4885CHRM1 4864/4885 |
| US-10640489-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | HSD11B1 940/4885CHRM2 47/4885CHRM1 7/4885 |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | HSD11B1 940/4885CHRM2 47/4885CHRM1 7/4885 |
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, ERBB2 | HSD11B1 776/4885CHRM2 4650/4885CHRM1 4555/4885 |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | HSD11B1 940/4885CHRM2 47/4885CHRM1 7/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | HSD11B1 3432/4885CHRM2 4820/4885CHRM1 4864/4885 |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | HSD11B1 940/4885CHRM2 47/4885CHRM1 7/4885 |
| US-11053218-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | HSD11B1 940/4885CHRM2 47/4885CHRM1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.